<DOC>
	<DOCNO>NCT00003992</DOCNO>
	<brief_summary>Randomized phase II trial study effectiveness chemotherapy paclitaxel monoclonal antibody trastuzumab follow chemotherapy treat woman stage II stage IIIA breast cancer overexpresses HER2 . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody locate tumor cell deliver tumor-killing substance without harm normal cell . Combining monoclonal antibody therapy chemotherapy may kill tumor cell .</brief_summary>
	<brief_title>Chemotherapy Plus Monoclonal Antibody Therapy Treating Women With Stage II Stage IIIA Breast Cancer That Overexpresses HER2</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety paclitaxel plus trastuzumab ( Herceptin ) follow adjuvant chemotherapy woman node positive stage II IIIa breast cancer HER2 overexpression . II . Evaluate safety long term trastuzumab ( Herceptin ) patient population . OUTLINE : This randomize study . Patients stratify accord radiotherapy ( none plan v plan breast chest wall ) . Patients randomize one two treatment arm . ARM I : Patients receive paclitaxel IV 3 hour immediately follow trastuzumab ( Herceptin ) IV 30-90 minute day 1 . Paclitaxel repeat every 3 week 4 course trastuzumab ( Herceptin ) repeat weekly 10 course . At 3 week follow paclitaxel trastuzumab ( Herceptin ) , patient receive doxorubicin IV cyclophosphamide IV 1 hour every 3 week 4 course . Following chemotherapy , estrogen receptor ( ER ) positive and/or progesterone receptor ( PR ) positive patient receive oral tamoxifen twice daily 5 year . ARM II : Patients receive therapy Arm I , except additional trastuzumab ( Herceptin ) IV weekly beginning within 3 week follow completion chemotherapy local therapy continue 1 year . ER and/or PR positive patient receive tamoxifen Arm I may concurrent trastuzumab ( Herceptin ) . Following completion doxorubicin cyclophosphamide , post lumpectomy post mastectomy patient may receive local radiotherapy daily 5-6 week . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 200 patient ( 100 per treatment arm ) accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II IIIa ( T1T3 , N1N2 , M0 ) adenocarcinoma breast HER2 overexpression ( 23+ immunochemistry ) Bilateral breast cancer allow Must local breast cancer surgery within past 12 week Mastectomy lumpectomy clear surgical margin AND axillary lymph node dissection least 6 node remove Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Bilirubin great 1.5 time upper limit normal ( ULN ) Creatinine great 1.5 time ULN LVEF least 50 % No history congestive cardiomyopathy No congestive heart failure myocardial infarction within past 6 month No uncontrolled hypertension No uncontrolled arrhythmia within past 6 month No prior malignancy within past 5 year except curatively treat basal squamous cell skin cancer carcinoma situ cervix No serious medical illness would limit survival less 2 year No psychiatric condition preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior chemotherapy breast cancer No prior hormonal therapy breast cancer At least one year since prior tamoxifen chemoprevention ( e.g. , Breast Cancer Prevention Trial ) No prior radiotherapy breast , chest wall , regional lymph node</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>